



ASX RELEASE

Race signs agreement with US-based IriSys LLC

25 October 2016, Perth, Australia: Race Oncology Limited (ASX: RAC) announced today that it has executed a development and manufacturing agreement with IriSys LLC in San Diego CA. Under the agreement, IriSys will complete the development of the final Bisantrone formulation and manufacture the finished product for NPP sales and use in further US clinical studies.

“The appointment of IriSys is an important milestone to Race, because it completes the chain of assets we need for successful production and marketing of Bisantrone,” said Race Managing Director, Peter Molloy. “All the pieces are now in place: Sai Life Sciences in India will manufacture the API, IriSys in San Diego will produce the finished product, and CarthaGenetics will manage the distribution and sales in Europe.” In addition, the Company is working with Camargo Pharmaceutical Services in the US, who are facilitating the regulatory process needed to open the way for sales and ongoing clinical studies.

“Bisantrone is a drug that has shown the potential to become an important new treatment for AML,” said Gerald Yakatan, founder, chairman and CEO of IriSys. “The scientific team at IriSys values the opportunity to work with Race Oncology on the development and manufacturing of Bisantrone.”

About IriSys

IriSys was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specialising in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and consulting related to the drug development process. IriSys’s custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving over 100 drug products from discovery to clinical development and commercialisation.

About Race Oncology

Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrone, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrone and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrone and bring this valuable cancer drug to market. Visit raceoncology.com for more information.

For more information:

Peter Molloy
Managing Director

T: +61 (0) 3 9097 1656
M: +61 (0) 418 174 816
E: plmolloy@raceoncology.com